Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report

Global and Region Duchenne Muscular Dystrophy (DMD) Therapeutics Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 31, 2022
  • PAGES：161
  • REPORT CODE：GMM936405
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Duchenne Muscular Dystrophy (DMD) Therapeutics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Duchenne Muscular Dystrophy (DMD) Therapeuticsmarket, defines the market attractiveness level of Duchenne Muscular Dystrophy (DMD) Therapeutics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Duchenne Muscular Dystrophy (DMD) Therapeutics industry, describes the types of Duchenne Muscular Dystrophy (DMD) Therapeutics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market and the development prospects and opportunities of Duchenne Muscular Dystrophy (DMD) Therapeutics industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Duchenne Muscular Dystrophy (DMD) Therapeutics market in Chapter 13.

    By Player:

    • Sarepta Therapeutics Inc

    • F Hoffmann-La Roche Ltd

    • Pfizer

    • Wave Life Sciences Ltd

    • Santhera Pharmaceuticals Inc

    By Type:

    • Pain Management Drugs

    • Corticosteroids

    • Prednisone

    • Deflazacort

    • Others

    By End-User:

    • Hospitals

    • Clinics

    • Home Care

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Duchenne Muscular Dystrophy (DMD) Therapeutics Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis and Outlook to 2022

    • 7.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    • 7.2 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    • 7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    • 7.4 China Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    • 7.5 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    • 7.6 India Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    • 7.7 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    8 Region and Country-wise Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis and Outlook to 2028

    • 8.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    • 8.2 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    • 8.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    • 8.4 China Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    • 8.5 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    • 8.6 India Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    • 8.7 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    9 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Outlook by Types and Applications to 2022

    • 9.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Pain Management Drugs Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Corticosteroids Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Prednisone Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Deflazacort Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Home Care Consumption and Growth Rate (2017-2022)

    10 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Outlook by Types and Applications to 2028

    • 10.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Pain Management Drugs Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Corticosteroids Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Prednisone Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Deflazacort Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Home Care Consumption Forecast and Growth Rate (2022-2028)

    11 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Analysis

    • 14.1 Sarepta Therapeutics Inc

      • 14.1.1 Sarepta Therapeutics Inc Company Details

      • 14.1.2 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Service

    • 14.2 F Hoffmann-La Roche Ltd

      • 14.2.1 F Hoffmann-La Roche Ltd Company Details

      • 14.2.2 F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Service

    • 14.3 Pfizer

      • 14.3.1 Pfizer Company Details

      • 14.3.2 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Service

    • 14.4 Wave Life Sciences Ltd

      • 14.4.1 Wave Life Sciences Ltd Company Details

      • 14.4.2 Wave Life Sciences Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Wave Life Sciences Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Service

    • 14.5 Santhera Pharmaceuticals Inc

      • 14.5.1 Santhera Pharmaceuticals Inc Company Details

      • 14.5.2 Santhera Pharmaceuticals Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Santhera Pharmaceuticals Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Duchenne Muscular Dystrophy (DMD) Therapeutics

    • Figure Duchenne Muscular Dystrophy (DMD) Therapeutics Picture

    • Table Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption by Country (2017-2022)

    • Figure United States Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure India Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure United States Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pain Management Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Corticosteroids Consumption and Growth Rate (2017-2022)

    • Figure Global Prednisone Consumption and Growth Rate (2017-2022)

    • Figure Global Deflazacort Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Home Care Consumption and Growth Rate (2017-2022)

    • Figure Global Pain Management Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Corticosteroids Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Prednisone Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Deflazacort Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Home Care Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Duchenne Muscular Dystrophy (DMD) Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Duchenne Muscular Dystrophy (DMD) Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    • Table Sarepta Therapeutics Inc (Foundation Year, Company Profile and etc.)

    • Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Service

    • Table F Hoffmann-La Roche Ltd (Foundation Year, Company Profile and etc.)

    • Table F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Service

    • Table Wave Life Sciences Ltd (Foundation Year, Company Profile and etc.)

    • Table Wave Life Sciences Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Wave Life Sciences Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Service

    • Table Santhera Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Santhera Pharmaceuticals Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Santhera Pharmaceuticals Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US